Overview of the pharmacogenomics of cigarette smoking

Cigarette smoking increases the risk of numerous health problems, including cancer, cardiovascular and pulmonary disorders, making smoking the leading cause of preventable death in the world. Nicotine is primarily responsible for the highly addictive properties of cigarettes. Although the majority of smokers express a desire to quit, few are successful in doing so. Twin and family studies have indicated substantial genetic contributions to smoking behaviors. One major research focus has been to elucidate the specific genes involved; this has been accomplished primarily through genome-wide linkage analyses and candidate gene association studies. Much attention has focused on genes involved in the neurotransmitter pathways for the brain reward system and genes altering nicotine metabolism. This paper reviews the current state of knowledge for genetic factors implicated in smoking behaviors, and examines how genetic variations may affect therapeutic outcomes for drugs used to assist smoking cessation.

[1]  M. Spitz,et al.  D2 dopamine receptor gene polymorphisms among African-Americans and Mexican-Americans: a lung cancer case-control study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[2]  R. Anney,et al.  Association Between Dependent Smoking and a Polymorphism in the Tyrosine Hydroxylase Gene in a Prospective Population-Based Study of Adolescent Health , 2004, Behavior genetics.

[3]  N E Morton,et al.  The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit , 2000, Annals of human genetics.

[4]  R. Wurtman,et al.  Effects of systemic nicotine on serotonin release in rat brain , 1993, Brain Research.

[5]  N. Martin,et al.  Defining nicotine dependence for genetic research: evidence from Australian twins , 2004, Psychological Medicine.

[6]  K. Hutchison,et al.  The DRD4 VNTR polymorphism influences reactivity to smoking cues. , 2002, Journal of abnormal psychology.

[7]  N. Hamajima,et al.  Association between the dopamine D2 receptor A2/A2 genotype and smoking behavior in the Japanese. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  J. Changeux,et al.  Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors , 2003, The European journal of neuroscience.

[9]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[10]  Michael C Neale,et al.  Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[11]  C. Husten,et al.  Cigarette smoking among adults--United States, 2006. , 2007, MMWR. Morbidity and mortality weekly report.

[12]  R. Drucker-Colín,et al.  Effects of nicotine and mecamylamine on rat dorsal raphe neurons. , 1998, European journal of pharmacology.

[13]  A. Elfarra,et al.  Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence for major roles by cytochromes P450 2A6 and 2E1. , 1994, Archives of biochemistry and biophysics.

[14]  D. Hamer,et al.  Lack of effect of D2 dopamine receptor TaqI A polymorphism on smoking cessation. , 2005, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[15]  D. Carmelli,et al.  Smoking and alcohol consumption in adult male twins: genetic heritability and shared environmental influences. , 1990, Journal of substance abuse.

[16]  C. Lerman,et al.  Stress-induced cigarette craving: effects of the DRD2 TaqI RFLP and SLC6A3 VNTR polymorphisms , 2004, The Pharmacogenomics Journal.

[17]  T. Arinami,et al.  Polymorphisms in genes involved in neurotransmission in relation to smoking. , 2000, European journal of pharmacology.

[18]  T. Fukami,et al.  CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS , 2005, Drug Metabolism and Disposition.

[19]  Z. Ismail,et al.  Nicotine and Endogenous Opioids: Toward Specific Pharmacotherapy , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[20]  L. Garofano,et al.  Association of the serotonin transporter promoter polymorphism with smoking behavior among adolescents , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[21]  J. Mallet,et al.  Quantitative effects on gene silencing by allelic variation at a tetranucleotide microsatellite. , 2001, Human molecular genetics.

[22]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[23]  D. Sarkar,et al.  The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. , 1997, Life sciences.

[24]  C. Lerman,et al.  Interacting effects of genetic predisposition and depression on adolescent smoking progression. , 2004, The American journal of psychiatry.

[25]  A. Ishizaka,et al.  Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms , 2006, European Respiratory Journal.

[26]  V. Höllt,et al.  Pharmacogenetics of opioid receptors and addiction , 2006, Pharmacogenetics and genomics.

[27]  D. Bertrand,et al.  Nicotine addiction: the possible role of functional upregulation. , 2002, Trends in pharmacological sciences.

[28]  C. Stockmeier,et al.  Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. , 1999, The Journal of pharmacology and experimental therapeutics.

[29]  Clinton D Kilts,et al.  The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density , 2005, BMC Genetics.

[30]  M. Stitzer,et al.  Pharmacotherapy for Nicotine Dependence 1 , 2005, CA: a cancer journal for clinicians.

[31]  C. Lerman,et al.  Effects of dopamine D2 receptor (DRD2) and transporter (SLC6A3) polymorphisms on smoking cue-induced cigarette craving among African-American smokers , 2005, Molecular Psychiatry.

[32]  Y. Funae,et al.  Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[33]  D. Lancet,et al.  Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes , 2006, Molecular Psychiatry.

[34]  P. Shields,et al.  Tryptophan hydroxylase gene variant and smoking behavior. , 2001, American journal of medical genetics.

[35]  A. Korten,et al.  Association of smoking and personality with a polymorphism of the dopamine transporter gene: results from a community survey. , 2000, American journal of medical genetics.

[36]  L. Almasy,et al.  Smoking behavior is under the influence of a major quantitative trait locus on human chromosome 5q , 1999, Genetic epidemiology.

[37]  M. Nakajima,et al.  TRANS-3′-HYDROXYCOTININE O- AND N-GLUCURONIDATIONS IN HUMAN LIVER MICROSOMES , 2005, Drug Metabolism and Disposition.

[38]  K. Matsuo,et al.  Association between smoking habits and dopamine receptor D2 taqI A A2 allele in Japanese males: a confirmatory study. , 2002, Journal of epidemiology.

[39]  M C Neale,et al.  A population-based twin study in women of smoking initiation and nicotine dependence , 1999, Psychological Medicine.

[40]  Y. Funae,et al.  Role of human cytochrome P4502A6 in C-oxidation of nicotine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[41]  M. Neale,et al.  Genome-wide Linkage Scan to Identify Loci for Age at First Cigarette in Dutch Sibling Pairs , 2006, Behavior genetics.

[42]  Ming D. Li,et al.  A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. , 2003, Addiction.

[43]  E. Bowman,et al.  EVIDENCE SUGGESTING THE ROLE OF SPECIFIC GENETIC FACTORS IN CIGARETTE SMOKING , 1998 .

[44]  P. Whiting,et al.  Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. , 1994, Molecular pharmacology.

[45]  N. Martin,et al.  Estimating two-stage models for genetic influences on alcohol, tobacco or drug use initiation and dependence vulnerability in twin and family data. , 2002, Twin research : the official journal of the International Society for Twin Studies.

[46]  N. Martin,et al.  Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. , 1993, Journal of substance abuse.

[47]  L. Epstein,et al.  Catechol-O-Methyl-Transferase Functional Polymorphism and Nicotine Dependence: an Evaluation of Nonreplicated Results , 2005, Cancer Epidemiology Biomarkers & Prevention.

[48]  K. Kiyotani,et al.  Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. , 2005, Biochemical and biophysical research communications.

[49]  K. Matsuo,et al.  Association of CYP2A6 Gene Deletion with Cigarette Smoking Status in Japanese Adults , 2003, Journal of epidemiology.

[50]  D Hoffmann,et al.  The relevance of tobacco-specific nitrosamines to human cancer. , 1989, Cancer surveys.

[51]  M. Munafo,et al.  Pharmacogenetics and nicotine addiction treatment. , 2005, Pharmacogenomics.

[52]  Ming D. Li,et al.  Ethnic- and gender-specific association of the nicotinic acetylcholine receptor alpha4 subunit gene (CHRNA4) with nicotine dependence. , 2005, Human molecular genetics.

[53]  E. Lander,et al.  Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results , 1995, Nature Genetics.

[54]  M. Munafo,et al.  Lack of Association of 5-HTTLPR Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial , 2006, Cancer Epidemiology Biomarkers & Prevention.

[55]  D. Grandy,et al.  The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. , 1989, American journal of human genetics.

[56]  L. Kozlowski,et al.  Influence of Smoking Fewer Cigarettes on Exposure to Tar, Nicotine, and Carbon Monoxide , 1987 .

[57]  D. Comings,et al.  Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors , 1997, Molecular Psychiatry.

[58]  R. Tyndale,et al.  Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence , 2005, Clinical pharmacology and therapeutics.

[59]  M. Tsuang,et al.  The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[60]  Ming D. Li The genetics of nicotine dependence , 2006, Current psychiatry reports.

[61]  P. Sullivan,et al.  Susceptibility genes for nicotine dependence: a genome scan and followup in an independent sample suggest that regions on chromosomes 2, 4, 10, 16, 17 and 18 merit further study , 1999, Molecular Psychiatry.

[62]  C. Ehlers,et al.  Genomic screen for loci associated with tobacco usage in Mission Indians , 2006, BMC Medical Genetics.

[63]  R. Tyndale,et al.  The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[64]  B R Flay,et al.  Stages in the development of adolescent smoking. , 2000, Drug and alcohol dependence.

[65]  R. Tyndale,et al.  Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers , 2004, Tobacco Control.

[66]  R. Tyndale,et al.  Nicotine metabolism defect reduces smoking , 1998, Nature.

[67]  A. Yoshino,et al.  Association study of brain-derived neurotrophic factor gene polymorphism and alcoholism. , 2004, Alcoholism, clinical and experimental research.

[68]  T. Clark,et al.  Polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers: seeking confirmation of the association in a follow-up study. , 2002, Pharmacogenetics.

[69]  R. Foxx,et al.  Nicotine's role in smoking: an analysis of nicotine regulation. , 1983, Psychological bulletin.

[70]  P. Sullivan,et al.  A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence , 2004, Psychological Medicine.

[71]  H. Checkoway,et al.  Genotype combinations for monoamine oxidase-B intron 13 polymorphism and dopamine D2 receptor TaqIB polymorphism are associated with ever-smoking status among men , 2005, Neuroscience Letters.

[72]  Jun Yokota,et al.  Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[73]  N. Martin,et al.  The Genetics of Smoking Persistence in Men and Women: A Multicultural Study , 1999, Behavior genetics.

[74]  M. Spitz,et al.  Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. , 1998, Journal of the National Cancer Institute.

[75]  H. Edenberg,et al.  The contribution of genetics to addiction therapy approaches. , 2005, Pharmacology & therapeutics.

[76]  L. Epstein,et al.  Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[77]  R. Tyndale,et al.  Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[78]  K. Bucholz,et al.  Common genetic vulnerability for nicotine and alcohol dependence in men. , 1999, Archives of general psychiatry.

[79]  R. Tyndale,et al.  A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[80]  L. Kozlowski,et al.  Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: failure to replicate and finding that never-smokers may be different. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[81]  G. Willemsen,et al.  Linkage analysis of smoking initiation and quantity in Dutch sibling pairs , 2004, The Pharmacogenomics Journal.

[82]  Mariza de Andrade,et al.  Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[83]  J. Feighner,et al.  Bupropion: a review of its mechanism of antidepressant activity. , 1995, The Journal of clinical psychiatry.

[84]  L. Cardon,et al.  The consumption of tobacco, alcohol, and coffee in Caucasian male twins: a multivariate genetic analysis. , 1996, Journal of substance abuse.

[85]  Gonneke Willemsen,et al.  Heritability of Smoking Initiation and Nicotine Dependence , 2005, Behavior genetics.

[86]  K. Kellar,et al.  Differential Regulation of Neuronal Nicotinic Receptor Binding Sites Following Chronic Nicotine Administration , 1997, Journal of neurochemistry.

[87]  Hongyu Zhao,et al.  A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus , 1998, Human Genetics.

[88]  G. Koob,et al.  Dramatic decreases in brain reward function during nicotine withdrawal , 1998, Nature.

[89]  J. Marx Drug development. Drugs inspired by a drug. , 2006, Science.

[90]  R. Perera,et al.  Nicotine replacement therapy for smoking cessation. , 2012, The Cochrane database of systematic reviews.

[91]  Ming D. Li,et al.  Single- and multilocus allelic variants within the GABA(B) receptor subunit 2 (GABAB2) gene are significantly associated with nicotine dependence. , 2005, American journal of human genetics.

[92]  M. Neville,et al.  Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1 , 2004, Human mutation.

[93]  M. Lynskey,et al.  The genetics of tobacco use: methods, findings and policy implications , 2002, Tobacco control.

[94]  J. Kaprio,et al.  Genetic Architecture of Smoking Behavior: A Study of Finnish Adult Twins , 2006, Twin Research and Human Genetics.

[95]  C. Lerman,et al.  An association of CYP2A6 genotype and smoking topography. , 2007, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[96]  David Goldman,et al.  COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. , 2005, Journal of studies on alcohol. Supplement.

[97]  S. Rogers,et al.  A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. , 1992, Molecular pharmacology.

[98]  Tianhua Niu,et al.  A common haplotype of the nicotine acetylcholine receptor alpha 4 subunit gene is associated with vulnerability to nicotine addiction in men. , 2004, American journal of human genetics.

[99]  Gail P Jarvik,et al.  Multiple genome-wide analyses of smoking behavior in the Framingham Heart Study , 2003, BMC Genetics.

[100]  Martin H. Schmidt,et al.  Association of the DRD4 exon III polymorphism with smoking in fifteen-year-olds: a mediating role for novelty seeking? , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.

[101]  A. Lajtha,et al.  The Effects of Cholinergic and Dopaminergic Antagonists on Nicotine-Induced Cerebral Neurotransmitter Changes , 2005, Neurochemical Research.

[102]  M. Loriot,et al.  Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. , 2001, Pharmacogenetics.

[103]  D. Murphy,et al.  A genetic association for cigarette smoking behavior. , 1999, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[104]  S. David,et al.  Comment on "The public health implications of smoking-induced decreased serum and red blood cell folate levels". , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[105]  A. Houdi,et al.  Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine: Evidence for nicotine-induced release of endogenous opioids in brain , 1990, Neuroscience Letters.

[106]  J. Changeux,et al.  Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine , 1998, Nature.

[107]  D. Comings,et al.  ORIGINAL RESEARCH ARTICLE Studies of the potential role of the dopamine D 1 receptor gene in addictive behaviors , 1997 .

[108]  A. Kastin,et al.  A potent and selective endogenous agonist for the mu-opiate receptor. , 1997, Nature.

[109]  M. Krebs,et al.  (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population , 2006, The Pharmacogenomics Journal.

[110]  R P Mattick,et al.  Quitting smoking: estimation by meta-analysis of the rate of unaided smoking cessation. , 2010, Australian journal of public health.

[111]  V. Hesselbrock,et al.  Results of a genomewide linkage scan: Support for chromosomes 9 and 11 loci increasing risk for cigarette smoking , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[112]  G. Swan,et al.  Non-replication of genetic association studies: is DAT all, folks? , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[113]  P. Sullivan,et al.  Haplotypes of four novel single nucleotide polymorphisms in the nicotinic acetylcholine receptor beta2-subunit (CHRNB2) gene show no association with smoking initiation or nicotine dependence. , 2000, American journal of medical genetics.

[114]  P. Männistö,et al.  Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. , 1999, Pharmacological reviews.

[115]  C. Lerman,et al.  Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation , 2006, Clinical pharmacology and therapeutics.

[116]  T. Niu,et al.  Association between polymorphism of the dopamine transporter gene and early smoking onset: an interaction risk on nicotine dependence , 2004, Journal of Human Genetics.

[117]  M. Munafo,et al.  Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial , 2004, BMJ : British Medical Journal.

[118]  R. Lukas,et al.  Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. , 1999, The Journal of pharmacology and experimental therapeutics.

[119]  Eric L. Barker,et al.  Serotonin transporters: Implications for antidepressant drug development , 2005, The AAPS Journal.

[120]  C. Jepson,et al.  Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy , 2006, Molecular Psychiatry.

[121]  G. Coetzee,et al.  Genetic variation of CYP2A6, smoking, and risk of cancer , 1999, The Lancet.

[122]  A. Goldstein,et al.  A genome‐wide search for loci contributing to smoking and alcoholism , 1999, Genetic epidemiology.

[123]  Ming D. Li,et al.  Significant association of BDNF haplotypes in European‐American male smokers but not in European‐American female or African‐American smokers , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[124]  D. Comings,et al.  The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. , 1996, Pharmacogenetics.

[125]  J O Rinne,et al.  The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers , 1998, Molecular Psychiatry.

[126]  X Li,et al.  Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. , 1992, Genomics.

[127]  Vincenzo De Luca,et al.  Evidence of Association between Smoking and α7 Nicotinic Receptor Subunit Gene in Schizophrenia Patients , 2004, Neuropsychopharmacology.

[128]  B. Greenberg,et al.  Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior , 2000, Molecular Psychiatry.

[129]  K. Franklin,et al.  The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine , 2005, Psychopharmacology.

[130]  C. McLoughlin Nicotine replacement. , 2005, Professional nurse.

[131]  S. David,et al.  No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. , 2002, Pharmacogenetics.

[132]  Ming D. Li,et al.  Significant Association of Catechol-O-Methyltransferase (COMT) Haplotypes with Nicotine Dependence in Male and Female Smokers of Two Ethnic Populations , 2006, Neuropsychopharmacology.

[133]  R. Walton,et al.  The dopamine D2 receptor C32806T polymorphism (DRD2 Taq1A RFLP) exhibits no association with smoking behaviour in a healthy UK population , 2004, Addiction biology.

[134]  K. Kendler,et al.  Tobacco consumption in Swedish twins reared apart and reared together. , 2000, Archives of general psychiatry.

[135]  R Freedman,et al.  Schizophrenia, sensory gating, and nicotinic receptors. , 1998, Schizophrenia bulletin.

[136]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[137]  Ming D. Li,et al.  A genome-wide scan to identify loci for smoking rate in the Framingham Heart Study population , 2003, BMC Genetics.

[138]  D. Grandy,et al.  Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. , 1991, Genomics.

[139]  Scott F. Saccone,et al.  Genetic analysis of maximum cigarette-use phenotypes , 2003, BMC Genetics.

[140]  R. Makuch,et al.  A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. , 2006, Archives of internal medicine.

[141]  R. Tyndale,et al.  Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. , 2000, Molecular pharmacology.

[142]  C. Husten,et al.  Cigarette Smoking Among Adults, United States , 2006 .

[143]  Yonghua Hu,et al.  Association between monoamine oxidase gene polymorphisms and smoking behaviour in Chinese males. , 2006, The international journal of neuropsychopharmacology.

[144]  R. Ebstein,et al.  Association of the serotonin transporter gene with smoking behavior. , 2005, The American journal of psychiatry.

[145]  R. J. Mitchell,et al.  Distribution of the 3' VNTR polymorphism in the human dopamine transporter gene in world populations. , 2000, Human biology.

[146]  Veena Kumari,et al.  Nicotine use in schizophrenia: The self medication hypotheses , 2005, Neuroscience & Biobehavioral Reviews.

[147]  D. Hamer,et al.  Genetic and functional analysis of single nucleotide polymorphisms in the beta2-neuronal nicotinic acetylcholine receptor gene (CHRNB2). , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[148]  P. Courtet,et al.  Suicidal behavior: Relationship between phenotype and serotonergic genotype , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.

[149]  P. Robledo,et al.  Nicotine-Induced Antinociception, Rewarding Effects, and Physical Dependence Are Decreased in Mice Lacking the Preproenkephalin Gene , 2005, The Journal of Neuroscience.

[150]  E. Bowman,et al.  Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[151]  L. Kozlowski,et al.  DAT's not all, but it may be more than we realize. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[152]  U. Spampinato,et al.  5-HT2A and 5-HT2C/2B Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and Striatum , 2002, Neuropsychopharmacology.

[153]  D. Mant,et al.  Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. , 2000, Pharmacogenetics.

[154]  Philip Asherson,et al.  Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1) , 2005, BMC Genetics.

[155]  D. Blakely,et al.  Population genetic study of the human dopamine transporter gene (DAT1) , 1995, Genetic epidemiology.

[156]  S. David,et al.  Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[157]  J. Jefferson,et al.  Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. , 2005, Clinical therapeutics.

[158]  N. Benowitz Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction. , 1988, The New England journal of medicine.

[159]  I. Ulmanen,et al.  Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. , 1995, Biochemistry.

[160]  N. Benowitz,et al.  Nicotine renal excretion rate influences nicotine intake during cigarette smoking. , 1985, The Journal of pharmacology and experimental therapeutics.

[161]  Hiroshi Yamamoto,et al.  Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans , 2001, Clinical pharmacology and therapeutics.

[162]  T. George,et al.  Co-morbidity of smoking in patients with psychiatric and substance use disorders. , 2005, The American journal on addictions.

[163]  N. Benowitz,et al.  Metabolism of nicotine to cotinine studied by a dual stable isotope method , 1994, Clinical pharmacology and therapeutics.

[164]  T. Arinami,et al.  Association between serotonin transporter gene polymorphism and smoking among Japanese males. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[165]  N. Martin,et al.  A Possible Smoking Susceptibility Locus on Chromosome 11p12: Evidence from Sex-limitation Linkage Analyses in a Sample of Australian Twin Families , 2006, Behavior genetics.

[166]  B. Cravatt,et al.  A missense mutation in human fatty acid amide hydrolase associated with problem drug use , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[167]  W. Tan,et al.  Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population , 2001, International journal of cancer.

[168]  Darrell R. Schroeder,et al.  A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation , 1997 .

[169]  C. Morris,et al.  Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population. , 1998, Pharmacogenetics.

[170]  T. Arinami,et al.  A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. , 1997, Human molecular genetics.

[171]  K. Matsuo,et al.  Monoamine oxidase polymorphisms and smoking behaviour in Japanese. , 2003, Pharmacogenetics.

[172]  Anna M. Lee,et al.  Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment , 2006, Journal of psychopharmacology.

[173]  B. Carter,et al.  A meta-analytic review of the CYP2A6 genotype and smoking behavior. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[174]  D. Balfour The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[175]  J. Changeux,et al.  Genetic dissociation of two behaviors associated with nicotine addiction: Beta-2 containing nicotinic receptors are involved in nicotine reinforcement but not in withdrawal syndrome , 2006, Psychopharmacology.

[176]  S. S. St. Jeor,et al.  D2 dopamine receptor gene and cigarette smoking: a reward gene? , 1994, Medical hypotheses.

[177]  R. Tyndale,et al.  Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking , 2000, Clinical pharmacology and therapeutics.

[178]  R. Tyndale,et al.  Genetics of alcohol and tobacco use in humans , 2003, Annals of medicine.

[179]  J. Blendy,et al.  μ-Opioid Receptor and CREB Activation Are Required for Nicotine Reward , 2005, Neuron.

[180]  C. Lerman,et al.  The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial , 2004, The Pharmacogenomics Journal.

[181]  D. Cook,et al.  CYP2A6, MAOA, DBH, DRD4, and 5HT2A genotypes, smoking behaviour and cotinine levels in 1518 UK adolescents , 2005, Pharmacogenetics and genomics.

[182]  R. Tyndale,et al.  Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. , 2004, Pharmacogenetics.

[183]  P. Shields,et al.  Lack of association of tyrosine hydroxylase genetic polymorphism with cigarette smoking. , 1997, Pharmacogenetics.

[184]  W. Geldenhuys,et al.  Brain Uptake Kinetics of Nicotine and Cotinine after Chronic Nicotine Exposure , 2005, Journal of Pharmacology and Experimental Therapeutics.

[185]  P. Sokoloff,et al.  Dopamine D3 Receptor Ligands Block Nicotine-Induced Conditioned Place Preferences through a Mechanism that does not Involve Discriminative-Stimulus or Antidepressant-Like Effects , 2005, Neuropsychopharmacology.

[186]  J. Yokota,et al.  Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. , 2004, Carcinogenesis.

[187]  M. Tsuang,et al.  Genetic and environmental contributions to smoking. , 1997, Addiction.

[188]  P. Sullivan,et al.  The genetic epidemiology of smoking. , 1999, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[189]  W. März,et al.  The serotonin transporter gene polymorphism is not associated with smoking behavior , 2006, The Pharmacogenomics Journal.

[190]  P. Shields,et al.  The role of the serotonin transporter gene in cigarette smoking. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[191]  N. Benowitz,et al.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity , 2004, Clinical pharmacology and therapeutics.

[192]  S. Wonnacott,et al.  Presynaptic nicotinic ACh receptors , 1997, Trends in Neurosciences.

[193]  R. Weinshilboum,et al.  Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. , 1996, Pharmacogenetics.

[194]  G. Swan,et al.  Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR , 2005, The Pharmacogenomics Journal.

[195]  K. Iwahashi,et al.  Lack of association between smoking and CYP2A6 gene polymorphisms in A Japanese population. , 2001, Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence.

[196]  B. Cravatt,et al.  Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. , 2004, Human molecular genetics.

[197]  L. Epstein,et al.  Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials , 2006, Neuropsychopharmacology.

[198]  J. Marx Drugs Inspired by a Drug , 2006, Science.

[199]  J. Zhang,et al.  Response of nicotine self-administration in the rat to manipulations of mu-opioid and γ-aminobutyric acid receptors in the ventral tegmental area , 2000, Psychopharmacology.

[200]  P. Sullivan,et al.  An association study of DRD5 with smoking initiation and progression to nicotine dependence. , 2001, American journal of medical genetics.

[201]  D. Hamer,et al.  A functional polymorphism in the monoamine oxidase A gene promoter , 1998, Human Genetics.

[202]  P. Sullivan,et al.  Association of the tryptophan hydroxylase gene with smoking initiation but not progression to nicotine dependence. , 2001, American journal of medical genetics.

[203]  M. Munafo,et al.  The genetic basis for smoking behavior: a systematic review and meta-analysis. , 2004, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[204]  L. Bierut,et al.  Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. , 2000, American journal of medical genetics.

[205]  G. Saucier,et al.  Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence , 1999, Molecular Psychiatry.

[206]  M. Reuter,et al.  Pleiotropic effect of the TPH A779C polymorphism on nicotine dependence and personality , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[207]  A. C. Collins,et al.  Nicotine Activation of α4* Receptors: Sufficient for Reward, Tolerance, and Sensitization , 2004, Science.

[208]  L. Cardon,et al.  Heavy consumption of cigarettes, alcohol and coffee in male twins. , 1997, Journal of studies on alcohol.

[209]  M. Nakajima,et al.  Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. , 2005, Drug metabolism and pharmacokinetics.

[210]  M. Damaj,et al.  Bupropion is a nicotinic antagonist. , 2000, The Journal of pharmacology and experimental therapeutics.

[211]  Caryn Lerman,et al.  Genetics and Drug Use as a Complex Phenotype , 2004, Substance use & misuse.

[212]  E K Perry,et al.  D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. , 1997, Pharmacogenetics.

[213]  L. Bierut,et al.  A genomic scan for habitual smoking in families of alcoholics: Common and specific genetic factors in substance dependence , 2004, American journal of medical genetics. Part A.

[214]  M. Farré,et al.  Drug addiction. , 2003, The New England journal of medicine.

[215]  Kiyoshi Inoue,et al.  Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes , 1999, Archives of Toxicology.

[216]  G. Uhl,et al.  A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. , 1992, Brain research. Molecular brain research.

[217]  E P Noble,et al.  Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. , 1991, Archives of general psychiatry.

[218]  W. Corrigall,et al.  Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area , 1994, Brain Research.

[219]  T Yamamoto,et al.  Nicotine metabolism and CYP2A6 allele frequencies in Koreans. , 2001, Pharmacogenetics.

[220]  M. Neale,et al.  The Genetics of Smoking Initiation and Quantity Smoked in Dutch Adolescent and Young Adult Twins , 1999, Behavior genetics.

[221]  Hiroshi Yamamoto,et al.  Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans , 2000, Clinical pharmacology and therapeutics.

[222]  Ming T. Tsuang,et al.  A Novel Permutation Testing Method Implicates Sixteen Nicotinic Acetylcholine Receptor Genes as Risk Factors for Smoking in Schizophrenia Families , 2004, Human Heredity.

[223]  R. Walton,et al.  Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. , 2004, Pharmacogenetics.

[224]  M. Krebs,et al.  Genetic vulnerability to drug abuse , 2000, European Psychiatry.

[225]  L. Epstein,et al.  Pharmacogenetic investigation of smoking cessation treatment. , 2002, Pharmacogenetics.

[226]  N. Martin,et al.  Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. , 1993, Addictive behaviors.

[227]  Makiko Maeda,et al.  CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation , 2006, The Pharmacogenomics Journal.

[228]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[229]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[230]  R. Anney,et al.  Nicotine dependence in a prospective population-based study of adolescents: the protective role of a functional tyrosine hydroxylase polymorphism. , 2004, Pharmacogenetics.

[231]  R Pickens,et al.  Genetic vulnerability to drug abuse. The D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. , 1992, Archives of general psychiatry.

[232]  T. Rebbeck,et al.  Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women , 2005, Pharmacogenetics and genomics.

[233]  K. Hashimoto,et al.  Association study between brain‐derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[234]  C. O'brien Anticraving medications for relapse prevention: a possible new class of psychoactive medications. , 2005, The American journal of psychiatry.

[235]  H. Feiler,et al.  A genome‐wide screen for nicotine dependence susceptibility loci , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.